Market Research Logo

Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

Summary


Rheumatoid arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years (Lefèvre et al., 2009). Disease progression results in stiffness and pain, especially in the hands and feet, which hinders mobility. Without treatment, the disease leads to joint destruction and disability. RA can have a substantial impact on quality of life and place a considerable economic burden upon the patient.

The advent of biologic disease-modifying anti-rheumatic drugs (DMARD) has boosted the rheumatoid arthritis (RA) market tremendously over the last two decades. The South-East Asia market, which for the purposes of this report comprises South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia, is forecast to grow at a compound annual growth rate (CAGR) of 4.7%, from USD1.04 Billion in 2015 to USD1.44 Billion in 2022. South Korea accounted for most of the market in 2015 with a 29.9% share, followed by Malaysia with 19.0%, the Philippines with 14.2%, Vietnam with 9.4%, Taiwan with 8.5%, Indonesia with 7.1%, Singapore with 6.4%, and Thailand with 5.5%.

The entry of new therapies over the forecast period will stimulate market growth. Promising pipeline candidates include Eli Lilly and Incyte’s baricitinib, Regeneron’s sarilumab, GlaxoSmithKline (GSK) and Johnson & Johnson’s sirukumab, Astellas’ peficitinib (ASP015K), and AbbVie’s upadacitinib. Galapagos’ filgotinib is in late-stage development, but it will not be launched during the forecast period, as its Phase III trial completion date is in Q3 2020.

The therapeutic market for RA has become extremely competitive owing to the number of new drug approvals. Competition for tumor necrosis factor alpha (TNF-α) inhibitors is particularly fierce and now dominates the treatment market for RA patients who are refractory to first-line DMARDs. In 2015, Humira (adalimumab), MabThera/Rituxan (rituximab) and Remicade (infliximab) were ranked among the top-10 best-selling drugs in the world, with global revenue of USD14.01 Billion, USD7.33 Billion and USD6.56 Billion, respectively, reflecting their groundbreaking clinical and commercial success.

The report ""Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs"" provides an introduction to rheumatoid arthritis (RA), covering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis, treatment guidelines and options, and co-morbidities and complications. Disease classification and methods of diagnosis are also provided.

In addition, this report also provides the following analysis -

  • Provides an overview of the RA marketed products landscape, including product profiles of key marketed products and heat maps that compare the safety and efficacy parameters of the various drugs.
  • Analyzes the RA pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target. The chapter concludes with an analysis of promising pipeline molecules, including product profiles and a heatmap that compares the efficacy and safety data for the various drugs.
  • Provides detailed analysis of recent clinical trials in RA by enrollment, duration and failure rate. Finally, promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
  • Supplies forecasts for the RA market, including epidemiology, treatment usage patterns, pricing, and market size, for the 2015–2022 period. The eight South-East Asia markets are covered and data are presented at a country level.
  • Provides detailed analysis of key market drivers and barriers for RA in South-East Asia markets.
Companies mentioned in this report: Eli Lilly and Incyte’s baricitinib, Regeneron’s sarilumab, GlaxoSmithKline (GSK) and Johnson & Johnson’s sirukumab, Astellas’ peficitinib (ASP015K), and AbbVie’s upadacitinib. Galapagos’ filgotinib

Scope

The current South-East Asia RA market contains novel products, including Xeljanz, a JAK inhibitor; and Actemra (tocilizumab), an IL-6 receptor inhibitor.
  • What are the competitive advantages of the existing novel drugs?
There are over 450 active pipeline molecules, and most of the late-stage investigational drug candidates feature improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.
  • Which classes of novel drugs are most prominent in the pipeline?
  • What is the potential for pipeline products to address unmet needs in the RA market?
Analysis of clinical trials since 2006 identified that the failure rates of RA molecules were highest in Phase II, at 72.6%, with the overall attrition rate for RA standing at 94.6%.
  • How do failure rates vary by stage of development, molecule type, and molecular target?
  • How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
Over the 2015-2022 forecast period, the South-East Asia RA therapeutics market is expected to increase in value at a CAGR of 4.7%, from $1.04 billion to over $1.4 billion.
  • Which markets make the most significant contribution to the current market size?
  • What are the epidemiology trends in these markets?
  • Will new market entrants lead to substantial changes in annual therapy costs?
  • How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?
Rising RA prevalence population and the uptake of newer therapies will lead to significant market growth over the forecast period, despite the launch of biosimilars of blockbuster anti-TNFs.
  • Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?
Reasons to buy

This report will enable you to -
  • Understand the clinical context of RA by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis and treatment guidelines and options.
  • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
  • Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
  • Consider market opportunities and potential risks by examining trends in RA clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.
  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in RA by examining clinical trial data and multi-scenario product forecast projections.
  • Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.
  • Discover trends in licensing and co-development deals concerning RA products and identify the major strategic consolidations that have shaped the commercial landscape.


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Disease Introduction
    • Epidemiology
      • Table RA Therapeutics Market, South-East Asia, Prevalence rate (%), 2015
    • Symptoms
    • Etiology and Pathophysiology
    • Diagnosis
      • Physical Examination
      • Blood Tests
      • 1987 Rheumatoid Arthritis Classification
      • 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis
        • Table ACR-EULAR Classification Criteria for Rheumatoid Arthritis, 2010
    • Prognosis
    • Treatment Guidelines and Options
      • Table Figure 1: American College of Rheumatology Treatment Guidelines, 2012
      • Pharmacological
      • Methotrexate
      • Hydroxychloroquine
      • Leflunomide
      • Sulfasalazine
      • Cyclosporine
      • Xeljanz (tofacitinib)
      • Other Non-biologics
      • Biologic Disease-Modifying Anti-rheumatic Drugs
      • Disease Scoring Methods for Measuring Treatment Efficacy
    • Co-infection or Co-morbidities
  • Marketed Products
    • Overview
    • Small-Molecule Disease-Modifying Anti-rheumatic Drugs
      • Methotrexate-Based Products
      • Xeljanz (tofacitinib) – Pfizer
    • Biologic Disease-Modifying Anti-rheumatic Drugs
      • Infliximab
      • Humira (adalimumab) – AbbVie
      • Etanercept
      • Rituximab
      • Orencia (abatacept) – Bristol-Myers Squibb
      • Simponi (golimumab) – Johnson & Johnson, Merck
      • Cimzia (certolizumab pegol) – UCB
      • Actemra (tocilizumab) – Roche
    • Comparative Efficacy and Safety of Marketed Products
      • Table Figure 2:RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Conventional Synthetic Disease Modifying Anti-rheumatic Marketed Products
      • Table Figure 3:RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for TNF-a Biologic Disease Modifying Anti-rheumatic Marketed Products
      • Table Figure 4:RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Non TNF-a Biologic Disease Modifying Anti-rheumatic Marketed Products
      • Table Figure 5:RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Targeted Synthetic Disease Modifying Anti-rheumatic Marketed Products
  • Pipeline Analysis
    • Overview
    • Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
      • Table Figure 6: RA Therapeutics Market, Global, Pipeline, 2016
    • Pipeline by Molecular Target
      • Table Figure 7 RA Therapeutics Market, Global, Pipeline by Molecular Target, 2016
      • Table Figure 8: RA Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016
    • Promising Pipeline Candidates
      • Baricitinib – Eli Lilly
        • Table Figure 9: RA Therapeutics Market, South-East Asia, Baricitinib Forecast ($m), 2017–2022
      • Sarilumab – Regeneron/Sanofi
        • Table Figure 10: RA Therapeutics Market, South-East Asia, Sarilumab Forecast ($m), 2018–2022
      • Sirukumab – Johnson & Johnson
        • Table Figure 11: RA Therapeutics Market, South-East Asia, Sirukumab Forecast ($m), 2018–2022
      • Peficitinib – Astellas
        • Table Figure 12: RA Therapeutics Market, South-East Asia, Peficitinib Forecast ($m), 2020–2022
      • Upadacitinib – AbbVie
        • Table Figure 13: RA Therapeutics Market, South-East Asia, Upadacitinib Forecast ($m), 2020–2022
      • Filgotinib – Galapagos
    • Comparative Efficacy and Safety of Pipeline Products
      • Table Figure 14:RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products
    • Product Competitiveness Framework
      • Table Figure 15:RA Therapeutics Market, Competitor Matrix for RA Marketed and Pipeline Products, 2016
  • Clinical Trial Analysis
    • Failure Rate
      • Overall Failure Rate
        • Table Figure 16: RA Therapeutics Market, Global, Average Clinical Trial Failure Rate (%), 2016
      • Failure Rate by Phase and Molecule Type
        • Table Figure 17: RA Therapeutics Market, Global, Clinical Trial Failure Rate by Molecule Type (%), 2006–2016
      • Failure Rate by Phase and Molecular Target
        • Table Figure 18: RA Therapeutics Market, Global, Clinical Trial Failure Rate by Molecular Target (%), 2006–2016
    • Clinical Trial Duration
      • Trial Duration by Stage of Development and Molecule Type
        • Table Figure 19: RA Therapeutics Market, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006–2016
      • Trial Duration by Stage of Development and Molecular Target
        • Table Figure 20: RA Therapeutics Market, Global, Clinical Trial Duration by Molecular Target, 2006–2016
    • Clinical Trial Size
      • Patient Enrollment per Product by Stage of Development and Molecule Type/Molecular Target
        • Table Figure 21: RA Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type,2006–2016
        • Table Figure 22: RA Therapeutics Market, Global, Clinical Trial Size per Product by Molecular Target, 2006–2016
      • Patient Enrollment per Trial by Stage of Development and Molecule Type/Molecular Target
        • Table Figure 23: RA Therapeutics Market, Global, Clinical Trial Size per Trial by Molecular Type,2006–2016
        • Table Figure 24: RA Therapeutics Market, Global, Clinical Trial Size per Trial by Molecular Target,2006–2016
    • Summary of Clinical Trial Metrics
      • Table Figure 25: RA Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecule Type
      • Table Figure 26: RA Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Multi-Scenario Forecast
    • Geographical Markets
    • South-East Asia Markets
      • Table Figure 27: RA Therapeutics Market, South-East Asia, Treatment Usage Patterns (million),2015–2022
      • Table Figure 28: RA Therapeutics Market, South-East Asia, Market Size ($bn),2015–2022
    • South Korea
      • Treatment Usage Patterns
        • Table Figure 29: RA Therapeutics Market, South Korea, Treatment Usage Patterns (million), 2015–2022
      • Annual Cost of Therapy
        • Table Figure 30: RA Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015–2022
      • Market Size
        • Table Figure 31: RA Therapeutics Market, South Korea, Market Size ($m), 2015–2022
    • Singapore
      • Treatment Usage Patterns
        • Table Figure 32: RA Therapeutics Market, Singapore, Treatment Usage Patterns (`000), 2015–2022
      • Annual Cost of Therapy
        • Table Figure 33: RA Therapeutics Market, Singapore, Annual Cost of Therapy ($), 2015–2022
      • Market Size
        • Table Figure 34: RA Therapeutics Market, Singapore, Market Size ($m), 2015–2022
    • Taiwan
      • Treatment Usage Patterns
        • Table Figure 35: RA Therapeutics Market, Taiwan, Treatment Usage Patterns (`000), 2015–2022
      • Annual Cost of Therapy
        • Table Figure 36: RA Therapeutics Market, Taiwan, Annual Cost of Therapy ($), 2015–2022
      • Market Size
        • Table Figure 37: RA Therapeutics Market, Taiwan, Market Size ($m), 2015–2022
    • Malaysia
      • Treatment Usage Patterns
        • Table Figure 38: RA Therapeutics Market, Malaysia, Treatment Usage Patterns (million), 2015–2022
      • Annual Cost of Therapy
        • Table Figure 39: RA Therapeutics Market, Malaysia, Annual Cost of Therapy ($), 2015–2022
      • Market Size
        • Table Figure 40: RA Therapeutics Market, Malaysia, Market Size ($m), 2015–2022
    • Philippines
      • Treatment Usage Patterns
        • Table Figure 41: RA Therapeutics Market, Philippines, Treatment Usage Patterns (million), 2015–2022
      • Annual Cost of Therapy
        • Table Figure 42: RA Therapeutics Market, Philippines, Annual Cost of Therapy ($), 2015–2022
      • Market Size
        • Table Figure 43: RA Therapeutics Market, Philippines, Market Size ($m), 2015–2022
    • Thailand
      • Treatment Usage Patterns
        • Table Figure 44: RA Therapeutics Market, Thailand, Treatment Usage Patterns (`000), 2015–2022
      • Annual Cost of Therapy
        • Table Figure 45: RA Therapeutics Market, Thailand, Annual Cost of Therapy ($), 2015–2022
      • Market Size
        • Table Figure 46: RA Therapeutics Market, Thailand, Market Size ($m), 2015–2022
    • Vietnam
      • Treatment Usage Patterns
        • Table Figure 47: RA Therapeutics Market, Vietnam, Treatment Usage Patterns (million), 2015–2022
      • Annual Cost of Therapy
        • Table Figure 48: RA Therapeutics Market, Vietnam, Annual Cost of Therapy ($), 2015–2022
      • Market Size
        • Table Figure 49: RA Therapeutics Market, Vietnam, Market Size ($m), 2015–2022
    • Indonesia
      • Treatment Usage Patterns
        • Table Figure 50: RA Therapeutics Market, Indonesia, Treatment Usage Patterns (million), 2015–2022
      • Annual Cost of Therapy
        • Table Figure 51: RA Therapeutics Market, Indonesia, Annual Cost of Therapy ($), 2015–2022
      • Market Size
        • Table Figure 52: RA Therapeutics Market, Indonesia, Market Size ($m), 2015–2022
    • Market Dynamics (Drivers and Barriers)
      • Drivers
      • Barriers
  • Deals and Strategic Consolidations
    • Licensing Deals
      • Deals by Region and Value
        • Table Figure 53: RA Therapeutics Market, Global, Licensing Deals by Region and Value, 2006–2016
      • Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
        • Table Figure 54: RA Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006–2016
      • Deal Value by Stage of Development, Molecule Type and Molecular Target
        • Table Figure 55: RA Therapeutics Market, Global, Licensing Deals by Stage of Development, and Deal Value, 2006–2016
        • Table Figure 56: RA Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006–2016
        • Table Figure 57: RA Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006–2016
      • Mylan Enters into Licensing Agreement with Momenta Pharmaceuticals for Biosimilar Candidates
      • Roche Enters into Licensing Agreement with Proximagen for VAP-1 Inhibitor
      • Alder Biopharmaceuticals Enters into Licensing Deal with Bristol-Myers Squibb and Alder Biopharmaceuticals for Clazakizumab
      • Ablynx Enters into a Licensing Deal with AbbVie for the Nanobody ALX-0061
        • Table RA Therapeutics Market, Global, Licensing Deals Valued over $10m, 2006–2016
    • Co-development
      • Deals by Region and Value
        • Table Figure 58: RA Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006–2016
      • Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
        • Table Figure 59: RA Therapeutics Market, Global, Number of Disclosed and Undisclosed Codevelopment Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006–2016
      • Deal Value by Stage of Development, Molecule Type, and Molecular Target
        • Table Figure 60: RA Therapeutics Market, Global, Co-development Deals by Stage of Development, and Deal Value, 2006–2016
        • Table Figure 61: RA Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2006–2016
        • Table Figure 62: Rheumatoid Arthritis Market, Global, Co-development Deals by Molecular Target, 2006–2016
      • Gilead Sciences Enters into Co-development Agreement with Galapagos
      • Nextera Enters into Research Agreement with Janssen Biotech
      • GlaxoSmithKline Enters into Global Agreement with Archemix
      • Chroma Therapeutics Enters into Co-development Agreement with GlaxoSmithKline
        • Table RA Therapeutics Market, Global, Co-development Deals Valued over $10m, 2006–2016
  • Appendix
    • All Pipeline Drugs by Stage of Development
      • Discovery
        • Table RA Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
      • Preclinical
        • Table RA Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
      • IND/CTA-filed
        • Table RA Therapeutics Market, Global, All Pipeline Products, Investigational New Drug, 2016
      • Phase I
        • Table RA Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
      • Phase II
        • Table RA Therapeutics Market, Global, All Pipeline Products, Phase II, 2016
      • Phase III
        • Table RA Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
      • Pre-registration
        • Table RA Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2016
    • Summary of Multi-Scenario Market Forecasts to 2022
      • Table RA Therapeutics Market, South-East Asia, Market Forecast, 2015–2022
      • Table RA Therapeutics Market, South Korea, Market Forecast, 2015–2022
      • Table RA Therapeutics Market, Singapore, Market Forecast, 2015–2022
      • Table RA Therapeutics Market, Taiwan, Market Forecast, 2015–2022
      • Table RA Therapeutics Market, Malaysia, Market Forecast, 2015–2022
      • Table RA Therapeutics Market, Philippines, Market Forecast, 2015–2022
      • Table RA Therapeutics Market, Thailand, Market Forecast, 2015–2022
      • Table RA Therapeutics Market, Vietnam, Market Forecast, 2015–2022
      • Table RA Therapeutics Market, Indonesia, Market Forecast, 2015–2022
    • Abbreviations
    • References
    • Research Methodology
      • Secondary Research
      • Marketed Product Profiles
      • Late-Stage Pipeline Candidates
      • Comparative Efficacy and Safety Heatmap for Marketed and Pipeline Products
      • Pipeline Analysis
      • Forecasting Model
      • Deals Data Analysis
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report